drugset / Trial / NCT04603872
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
RandomizedParallel-groupSingle-blindTreatment
Summary
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Timeline
- Start
- 2020-11-01
- Primary completion
- 2023-11-01
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/BCMA Targeted CAR T-cells | Cell therapy | — | Intravenous |
| Subject | dasatinib anhydrous | Small molecule | — | — |